Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Marks, 2001, Histone deacetylases and cancer: causes and therapies., Nat Rev Cancer, 1, 194, 10.1038/35106079 Timmermann, 2001, Histone acetylation and disease., Cell Mol Life Sci, 58, 728, 10.1007/PL00000896 Villar-Garea, 2004, Histone deacetylase inhibitors: understanding a new wave of anticancer agents., Int J Cancer, 112, 171, 10.1002/ijc.20372 Glick, 1999, Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma., Cancer Res, 59, 4392 Peart, 2005, Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors., Proc Natl Acad Sci U S A, 102, 3697, 10.1073/pnas.0500369102 Ruefli, 2001, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species., Proc Natl Acad Sci U S A, 98, 10833, 10.1073/pnas.191208598 Amin, 2001, Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)., Br J Haematol, 115, 287, 10.1046/j.1365-2141.2001.03123.x He, 2001, Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia., J Clin Invest, 108, 1321, 10.1172/JCI200111537 Mitsiades, 2003, Molecular sequelae of histone deacetylase inhibition in human malignant B cells., Blood, 101, 4055, 10.1182/blood-2002-11-3514 Nimmanapalli, 2003, Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells., Blood, 101, 3236, 10.1182/blood-2002-08-2675 Sakajiri, 2005, Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines., Exp Hematol, 33, 53, 10.1016/j.exphem.2004.09.008 Yu, 2003, Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells., Cancer Res, 63, 2118 Mitsiades, 2003, Novel biologically based therapies for Waldenstrom's macroglobulinemia., Semin Oncol, 30, 309, 10.1053/sonc.2003.50065 Sanchez-Gonzalez, 2006, Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor., Blood, 108, 1174, 10.1182/blood-2005-09-008086 Reddy, 2004, Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect., Proc Natl Acad Sci U S A, 101, 3921, 10.1073/pnas.0400380101 Kelly, 2005, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer., J Clin Oncol, 23, 3923, 10.1200/JCO.2005.14.167 O'Connor, 2006, Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies., J Clin Oncol, 24, 166, 10.1200/JCO.2005.01.9679 Richardson, 2004, Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma (MM) [abstract]., Blood, 104, 420, 10.1182/blood.V104.11.1503.1503 Rubin, 2006, A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer., Clin Cancer Res, 12, 7039, 10.1158/1078-0432.CCR-06-1802 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)., Blood, 109, 31, 10.1182/blood-2006-06-025999 Olsen, 2007, A Phase IIb multicenter trial of Vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with persistent, progressive or treatment refractory cutaneous T-cell lymphoma., J Clin Oncol, 25, 3109, 10.1200/JCO.2006.10.2434 Gore, 2002, Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia., Clin Cancer Res, 8, 963 Kuendgen, 2006, The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia., Cancer, 106, 112, 10.1002/cncr.21552 Byrd, 2005, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia., Blood, 105, 959, 10.1182/blood-2004-05-1693 Odenike, 2006, The histone deacetylase inhibitor (HDI) depsipeptide has differential activity in core binding factor AML [abstract]., Blood, 108, 553, 10.1182/blood.V108.11.1956.1956 Garcia-Manero, 2006, Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS)., J Clin Oncol, 24, 337s, 10.1200/jco.2006.24.18_suppl.6500 Lancet, 2006, A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS) [abstract]., Blood, 108, 558 Giles, 2006, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies., Clin Cancer Res, 12, 4628, 10.1158/1078-0432.CCR-06-0511 Gojo, 2007, Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias., Blood, 109, 2781, 10.1182/blood-2006-05-021873 Ottmann, 2004, A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies., J Clin Oncol, 22, 3024, 10.1200/jco.2004.22.14_suppl.3024 National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Accessed January 16, 2007 http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Cheson, 2003, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia., J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 Cheson, 1996, National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment., Blood, 87, 4990, 10.1182/blood.V87.12.4990.bloodjournal87124990 Hughes, 2001, Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer., Nat Biotechnol, 19, 342, 10.1038/86730 Van't Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer., Nature, 415, 530, 10.1038/415530a Yu, 2003, Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways., Cancer Biol Ther, 2, 544, 10.4161/cbt.2.5.454 Kelly, 2003, Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously., Clin Cancer Res, 9, 3578 Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia., Blood, 108, 3271, 10.1182/blood-2006-03-009142 Garcia-Manero, 2007, Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)., J Clin Oncol, 25, 372s, 10.1200/jco.2007.25.18_suppl.7062 Gore, 2006, Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage [abstract]., Blood, 108, 156, 10.1182/blood.V108.11.517.517 Soriano, 2007, Significant clinical activity of the combination of 5-azacitidine, valproic acid and all-trans retinoic (ATRA) acid in leukemia: results of a phase I/II study., Blood, 110, 2302, 10.1182/blood-2007-03-078576 Dai, 2005, A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients., Cancer Res, 65, 4059, 10.1158/0008-5472.CAN-04-3953 Whitfield, 2006, Common markers of proliferation., Nat Rev Cancer, 6, 99, 10.1038/nrc1802 Kamio, 2003, B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs., Blood, 102, 3317, 10.1182/blood-2002-12-3656 Butler, 2002, The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin., Proc Natl Acad Sci U S A, 99, 11700, 10.1073/pnas.182372299 Marks, 2006, Thioredoxin in cancer: role of histone deacetylase inhibitors., Semin Cancer Biol, 16, 436, 10.1016/j.semcancer.2006.09.005 Pei, 2004, Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors., Clin Cancer Res, 10, 3839, 10.1158/1078-0432.CCR-03-0561 Swain, 2006, A step in the right direction., J Clin Oncol, 24, 3717, 10.1200/JCO.2006.06.7025